Loading quotes...

Forecast

The analysts' average price target is €93.66 (+15.79%). The median is €94.44 (+16.75%).

Buy	33
Hold	16
Sell	0

News Go to news feed

CMS guideline on TAVR reimbursement strengthens Edwards Lifesciences

US agency CMS has published a final national reimbursement guideline for TAVR that also provides reimbursement for asymptomatic aortic stenosis, thereby strengthening the TAVR market. Stifel views the decision as positive for Edwards Lifesciences and expects it to support the long-term revenue growth forecast of over 10%. The guideline retains case volume requirements and the role of the heart team including cardiac surgeons, but allows asynchronous chart review and requires only a single TAVR operator in the room, which increases procedural efficiency. CMS also announced a national review of reimbursement for TAVR in aortic regurgitation, expected to conclude on June 8, 2027. » More on de.investing.com
Edwards Lifesciences noted as leader in TAVR growth by Aristotle Value fund

Aristotle Capital's Value Equity Fund highlighted Edwards Lifesciences for its leadership in transcatheter aortic valve replacement (TAVR) and structural heart therapies, citing the procedure's role in expanding patient eligibility and market adoption. The fund referenced Edwards' market position and recent stock range, with shares around $90.78 and a market cap near $51.8 billion. The mention came in the fund's Q2 2026 letter, which contrasted its own underperformance versus AI-driven index gains while still listing Edwards among notable holdings. 68 hedge funds held Edwards at the end of Q1 2026, up from 64 the prior quarter. » More on finance.yahoo.com
Edwards Lifesciences reaches new 52-week high at 92.94 USD

Shares of Edwards Lifesciences rose to a 52-week high of 92.94 USD and are currently trading just below that level; year-to-date the stock is up about 20.09%. The company trades at a P/E ratio of 50.01 and is considered overvalued by InvestingPro. At the New York Valves 2026 conference Edwards presented data from the PROGRESS study on TAVR, and the U.S. government proposed a National Coverage Decision memorandum for TAVR, which analysts view positively. Leerink reiterated "Market Perform" with a price target of 87 USD, TD Cowen raised its target to 104 USD; Theodora Mistras was also appointed as the new chief financial officer. » More on de.investing.com

Financials

In the last quarter, Edwards Lifesciences had revenue of €1.53bn and net profit of €211.96m

(EUR)	June 2026	YoY
Revenue	1.53bn	17.35%
Gross profit	1.18bn	17.24%
Net profit	211.96m	24.25%
EBITDA	492.61m	45.08%

Fundamentals

Metric	Value
Market capitalization	€45.96bn
Number of shares	576.4m
52-week high/low	€86.20 - €66.83
Dividends	No
Beta	0.86
P/E ratio	51.19
PEG ratio	-0.68
P/B ratio	4.84
P/S ratio	7.88

Company profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Name	Edwards Lifesciences
CEO	Bernard J. Zovighian
Headquarters	Irvine, ca USA
Website	edwards.com
Sector	Health Care
Industry	Biotechnology
IPO	27/03/2000
Employees	16,000